Author
Listed:
- Miriam Martínez-Santos
- María Ybarra
- Maria E Pires
- Chiara Ceresoni
- Elías Martínez-López
- Javier Sancho-Pelluz
- Maria Oltra
- Jorge M Barcia
Abstract
Purpose: To evaluate the diagnostic accuracy of circulating miRNAs in distinguishing between different diabetic retinopathy (DR) stages in type 2 diabetes mellitus (T2DM). Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA-DTA and Cochrane guidelines. The protocol was not registeres and no external funding was received. A comprehensive search was performed in PubMed, CENTRAL, Scopus, Web of Science, ScienceDirect, and ClinicalTrials (up to January 2025) to identify diagnostic test accuracy studies on circulating miRNAs for DR. Eligible studies included three predefined comparisons: healthy controls versus DR (CTL vs DR), T2DM without DR versus DR (T2DM vs DR), and non-proliferative versus proliferative DR (NPDR vs PDR). DR diagnosis was confirmed using fundus fluorescein angiography and/or fundus examination. Two reviewers independently conducted study selection, data extraction, and risk of bias assessment with QUADAS-2; certainty of evidence was assessed using GRADE. Data were synthesized using a bivariate random-effects meta-analysis, with subgroup analyses, meta-regression, and sensitivity analyses to explore heterogeneity. Data were synthesized via a bivariate random-effects meta-analysis, with subgroup analyses, meta-regression, and sensitivity tests to explore heterogeneity. Results: Sixteen studies (1849 participants; 21 miRNAs) were included. For CTL vs DR (7 studies), pooled sensitivity was 77% (70–82) and specificity 84% (77–89), AUC 0.86 (0.82–0.89). For T2DM vs DR (9 studies), sensitivity was 81% (75–86) and specificity 80% (71–87), AUC 0.88 (0.84–0.91). For NPDR vs PDR (12 studies), sensitivity was 84% (79–87) and specificity 82% (76–88), AUC 0.90 (0.87–0.93). Heterogeneity arose chiefly from sample matrix, normalization strategies and inter-study expression trends. Patient selection posed the greatest bias risk. Conclusions: Circulating miRNAs exhibit promising diagnostic accuracy for differentiating among various stages of DR. However, future large, prospective studies in diverse populations and standardized pre-analytical protocols are required to confirm and translate these findings.
Suggested Citation
Miriam Martínez-Santos & María Ybarra & Maria E Pires & Chiara Ceresoni & Elías Martínez-López & Javier Sancho-Pelluz & Maria Oltra & Jorge M Barcia, 2025.
"Circulating microRNAs as biomarkers for diabetic retinopathy stage identification: A DTA systematic review and meta-analysis,"
PLOS ONE, Public Library of Science, vol. 20(11), pages 1-20, November.
Handle:
RePEc:plo:pone00:0335434
DOI: 10.1371/journal.pone.0335434
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0335434. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.